Business
Aprea is a clinical-stage precision oncology company developing targeted therapies for biomarker-defined cancers.
Aprea had no revenue, narrowed its net loss to $12.6M, and improved free cash flow to negative $12.9M.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage oncologyNote
- Revenue — No revenue in the bundleNote
- Profitability — Net loss narrowed to $12.6MNote
- Cash — FCF improved to negative $12.9MNote
- Balance sheet — Equity fell 35.6%Watch
- Insiders — 4 buys / 0 sellsOK
- Accounting — No forensic screen in bundleNote
Leadership changes
From Aprea Therapeutics, Inc.'s own filings, the day they're filed.
- Christian S. Schade · Chairperson · departureeff. 2023-08-23
- Richard Peters · Chairperson · departureeff. 2023-08-23
- Jean-Pierre Bizzari · director · departureeff. 2023-08-23
Latest filings
- 8-K · Company announcement2026-08-28
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-07-23
- 8-K · Company announcement2026-06-17
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aprea Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.